Symbols / IBIO Stock $1.90 -1.55% iBio, Inc.

Healthcare • Biotechnology • United States • NCM
IBIO (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Martin B. Brenner D.V.M., Ph.D.
Exch · Country NCM · United States
Market Cap 94.39M
Enterprise Value 21.92M
Income -27.61M
Sales 300.00K
FCF (ttm) -14.94M
Book/sh 2.25
Cash/sh 1.51
Employees 20
Insider 10d —
IPO Aug 19, 2008
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -6.01
PEG —
P/S 314.63
P/B 0.85
P/C —
EV/EBITDA -0.78
EV/Sales 73.06
Quick Ratio 11.50
Current Ratio 11.88
Debt/Eq 3.00
LT Debt/Eq —
EPS (ttm) -0.56
EPS next Y -0.32
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-02-10
Earnings (prior) 2026-02-10
ROA -34.50%
ROE -62.09%
ROIC —
Gross Margin 100.00%
Oper. Margin -96.53%
Profit Margin 0.00%
Shs Outstand 49.68M
Shs Float 39.32M
Insider Own 1.71%
Instit Own 46.88%
Short Float 6.90%
Short Ratio 3.42
Short Interest 3.41M
52W High 3.82
vs 52W High -50.26%
52W Low 0.56
vs 52W Low 239.29%
Beta —
Impl. Vol. —
Rel Volume 0.34
Avg Volume 944.71K
Volume 324.27K
Target (mean) $5.53
Tgt Median $5.50
Tgt Low $4.20
Tgt High $7.00
# Analysts 6
Recom None
Prev Close $1.93
Price $1.90
Change -1.55%
About

iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein. Its product pipelines for cardiometabolic disease area include IBIO-101, an anti-CD25 Mab that binds and depletes immunosuppressive regulatory treg cells to inhibit the growth of solid tumors; CCR8, an antibody that enhance the body's immune response against cancer cells; and MUC16 antibodies. In addition, the company is developing EGFRvIII, an antibody therapeutics that targets EGFRvIII protein with the aim to address these cancer types without affecting healthy cells; and TROP-2 x CD3 bispecific antibody that is developed with EngageTx platform to harness T cells to kill TROP-2–expressing tumors while minimizing the cytokine release that often limits the tolerability of T-cell engagers. It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases. The company was formerly known as iBioPharma, Inc. and changed its name to iBio, Inc. in August 2009. iBio, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$5.53
Mean price target
2. Current target
$1.90
Latest analyst target
3. DCF / Fair value
$-5.41
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.90
Low
$4.20
High
$7.00
Mean
$5.53

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-09 main Chardan Capital Buy → Buy $5
2026-03-18 main Chardan Capital Buy → Buy $5
2026-03-03 init Jones Trading — → Buy $7
2026-02-12 main Chardan Capital Buy → Buy $5
2025-10-21 init Oppenheimer — → Outperform $5
2025-10-17 init Leerink Partners — → Outperform $2
2025-06-25 main Chardan Capital Buy → Buy $5
2025-05-06 main Chardan Capital Buy → Buy $5
2025-05-05 main Chardan Capital Buy → Buy $5
2024-12-17 init LUCID CAPITAL MARKETS — → Buy $6
2024-07-22 init Brookline Capital — → Buy $4
2024-06-03 main Chardan Capital Buy → Buy $5
2024-05-28 init Chardan Capital — → Buy $5
News
RSS: Latest IBIO news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-26 BANJAK MARC Officer — 13,934 $1.64 $23,055
2026-03-19 BRENNER MARTIN Chief Executive Officer — 12,336 $2.02 $24,919
2026-03-19 DURAN FELIPE Chief Financial Officer — 24,835 $2.02 $50,132
2025-01-10 ARKOWITZ DAVID A. Director — 18,382 $2.72 $49,999
2025-01-10 CLARK WILLIAM D Director — 1,838 $2.72 $4,999
2025-01-10 SENDER GARY L. Director — 9,191 $2.72 $25,000
2025-01-10 BRENNER MARTIN Chief Executive Officer — 9,191 $2.72 $25,000
2025-01-10 DURAN FELIPE Chief Financial Officer — 9,191 $2.72 $25,000
2025-01-10 BANJAK MARC Officer — 9,191 $2.72 $25,000
2025-01-10 PARADA ANTONIO BERNARDINO GUIMARAES Director — 183,823 $2.72 $499,999
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total Revenue
0.40
+77.78%
0.23
0.00
-100.00%
1.88
Operating Revenue
0.40
+77.78%
0.23
0.00
-100.00%
1.88
Cost Of Revenue
—
—
—
0.22
Reconciled Cost Of Revenue
—
—
—
0.22
Gross Profit
—
—
—
2.17
Operating Expense
19.00
+12.71%
16.86
-42.55%
29.34
-7.09%
31.58
Research And Development
8.31
+60.31%
5.18
-49.79%
10.33
+5.09%
9.83
Selling General And Administration
10.69
-8.43%
11.67
-38.61%
19.02
-12.59%
21.75
General And Administrative Expense
10.69
-8.43%
11.67
-38.61%
19.02
-12.59%
21.75
Other Gand A
10.69
-8.43%
11.67
-38.61%
19.02
-12.59%
21.75
Total Expenses
19.00
+12.71%
16.86
-42.55%
29.34
-7.09%
31.58
Operating Income
-18.60
-11.83%
-16.63
+43.31%
-29.34
+1.19%
-29.70
Total Operating Income As Reported
-18.60
-11.83%
-16.63
+43.31%
-29.34
+1.19%
-29.70
EBITDA
-17.04
-21.52%
-14.02
+49.65%
-27.85
-8.27%
-25.72
Normalized EBITDA
-17.04
-13.43%
-15.02
+45.87%
-27.75
-7.88%
-25.72
Reconciled Depreciation
1.13
-9.92%
1.25
-9.42%
1.38
-63.60%
3.79
EBIT
-18.16
-18.95%
-15.27
+47.75%
-29.23
+0.97%
-29.51
Total Unusual Items
0.00
-100.00%
1.00
+1120.41%
-0.10
-116.14%
0.61
Total Unusual Items Excluding Goodwill
0.00
-100.00%
1.00
+1120.41%
-0.10
-116.14%
0.61
Special Income Charges
0.00
-100.00%
1.00
0.00
-100.00%
0.61
Other Special Charges
—
—
—
-0.61
Net Income
-18.38
+26.22%
-24.91
+61.69%
-65.01
-29.01%
-50.39
Pretax Income
-18.38
-19.00%
-15.44
+47.31%
-29.31
+0.68%
-29.51
Net Non Operating Interest Income Expense
0.23
+17.80%
0.19
+46.92%
0.13
-26.55%
0.18
Interest Expense Non Operating
0.21
+23.26%
0.17
+107.23%
0.08
0.00
Net Interest Income
0.23
+17.80%
0.19
+46.92%
0.13
-26.55%
0.18
Interest Expense
0.21
+23.26%
0.17
+107.23%
0.08
0.00
Interest Income Non Operating
0.44
+20.39%
0.36
+70.42%
0.21
+20.34%
0.18
Interest Income
0.44
+20.39%
0.36
+70.42%
0.21
+20.34%
0.18
Other Income Expense
—
1.00
+1120.41%
-0.10
-1500.00%
0.01
Other Non Operating Income Expenses
—
—
—
0.01
Gain On Sale Of Security
—
—
-0.10
—
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-18.38
+26.22%
-24.91
+61.69%
-65.01
-29.01%
-50.39
Net Income From Continuing Operation Net Minority Interest
-18.38
-19.00%
-15.44
+47.31%
-29.31
+0.68%
-29.51
Net Income From Continuing And Discontinued Operation
-18.38
+26.22%
-24.91
+61.69%
-65.01
-29.24%
-50.30
Net Income Continuous Operations
-18.38
-19.00%
-15.44
+47.31%
-29.31
+0.68%
-29.51
Net Income Discontinuous Operations
0.00
+100.00%
-9.46
+73.49%
-35.70
-71.70%
-20.79
Minority Interests
—
—
0.00
-100.00%
0.00
Normalized Income
-18.38
-11.76%
-16.44
+43.71%
-29.21
+1.01%
-29.51
Net Income Common Stockholders
-18.38
+26.22%
-24.91
+61.69%
-65.01
-29.01%
-50.39
Diluted EPS
-1.75
+73.08%
-6.50
+93.88%
-106.19
+8.14%
-115.60
Basic EPS
-1.75
+73.08%
-6.50
+93.88%
-106.19
+8.14%
-115.60
Basic Average Shares
10.50
+174.05%
3.83
+525.98%
0.61
+40.35%
0.44
Diluted Average Shares
10.50
+174.05%
3.83
+525.98%
0.61
+40.35%
0.44
Diluted NI Availto Com Stockholders
-18.38
+26.22%
-24.91
+61.69%
-65.01
-29.01%
-50.39
Gain On Sale Of PPE
0.00
-100.00%
1.00
0.00
—
Net Income From Tax Loss Carryforward
—
—
0.00
+100.00%
-0.09
Preferred Stock Dividends
—
—
—
0.09
Line Item Trend 2024-06-30
Total Assets
28.73
Current Assets
15.67
Cash Cash Equivalents And Short Term Investments
14.21
Cash And Cash Equivalents
14.21
Other Short Term Investments
—
Receivables
0.71
Accounts Receivable
—
Other Receivables
—
Inventory
—
Raw Materials
—
Work In Process
—
Prepaid Assets
—
Restricted Cash
0.00
Assets Held For Sale Current
0.00
Other Current Assets
0.75
Total Non Current Assets
13.06
Net PPE
6.37
Gross PPE
7.86
Accumulated Depreciation
-1.49
Properties
0.00
Buildings And Improvements
0.69
Machinery Furniture Equipment
3.95
Construction In Progress
—
Other Properties
3.21
Goodwill And Other Intangible Assets
5.37
Other Intangible Assets
5.37
Non Current Accounts Receivable
—
Non Current Prepaid Assets
0.03
Other Non Current Assets
0.21
Total Liabilities Net Minority Interest
7.41
Current Liabilities
3.84
Payables And Accrued Expenses
1.12
Payables
0.66
Accounts Payable
0.36
Other Payable
0.30
Current Accrued Expenses
0.46
Pensionand Other Post Retirement Benefit Plans Current
1.57
Total Tax Payable
0.00
Current Debt And Capital Lease Obligation
0.95
Current Debt
0.22
Other Current Borrowings
0.22
Current Capital Lease Obligation
0.73
Current Deferred Liabilities
0.20
Current Deferred Revenue
0.20
Other Current Liabilities
—
Total Non Current Liabilities Net Minority Interest
3.57
Liabilities Heldfor Sale Non Current
—
Long Term Debt And Capital Lease Obligation
3.51
Long Term Debt
0.77
Long Term Capital Lease Obligation
2.74
Tradeand Other Payables Non Current
0.06
Stockholders Equity
21.32
Common Stock Equity
21.32
Capital Stock
0.01
Common Stock
0.01
Preferred Stock
0.00
Share Issued
8.62
Ordinary Shares Number
8.62
Treasury Shares Number
0.00
Additional Paid In Capital
335.16
Retained Earnings
-313.85
Gains Losses Not Affecting Retained Earnings
—
Minority Interest
—
Other Equity Adjustments
—
Total Equity Gross Minority Interest
21.32
Total Capitalization
22.09
Working Capital
11.83
Invested Capital
22.31
Total Debt
4.46
Net Debt
—
Capital Lease Obligations
3.48
Net Tangible Assets
15.96
Tangible Book Value
15.96
Current Notes Payable
0.00
Interest Payable
0.00
Non Current Accrued Expenses
—
Non Current Note Receivables
1.08
Notes Receivable
0.71
Line Item Trend 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Operating Cash Flow
-15.30
+17.52%
-18.55
+39.04%
-30.44
+18.79%
-37.48
Cash Flow From Continuing Operating Activities
-15.30
+17.52%
-18.55
+39.04%
-30.44
+18.79%
-37.48
Net Income From Continuing Operations
-18.38
+26.22%
-24.91
+61.69%
-65.01
-29.23%
-50.30
Depreciation Amortization Depletion
1.13
-9.92%
1.25
-9.42%
1.38
-63.60%
3.79
Depreciation
1.11
-10.08%
1.23
-1.91%
1.25
-63.01%
3.39
Amortization Cash Flow
0.02
+0.00%
0.02
-84.13%
0.13
-68.58%
0.40
Depreciation And Amortization
1.13
-9.92%
1.25
-9.42%
1.38
-63.60%
3.79
Amortization Of Intangibles
0.02
+0.00%
0.02
-84.13%
0.13
-68.58%
0.40
Other Non Cash Items
-0.06
-293.75%
0.03
-80.84%
0.17
+421.15%
-0.05
Stock Based Compensation
1.53
-24.93%
2.04
-53.59%
4.39
+0.32%
4.38
Provisionand Write Offof Assets
—
0.00
-100.00%
4.92
0.00
Asset Impairment Charge
0.00
-100.00%
3.10
-83.21%
18.46
+949.15%
1.76
Operating Gains Losses
—
3.10
+556.03%
-0.68
-12.03%
-0.61
Gain Loss On Investment Securities
—
—
0.10
—
Gain Loss On Sale Of PPE
0.00
-100.00%
3.91
+605.69%
-0.77
0.00
Change In Working Capital
0.48
+115.12%
-3.17
-153.98%
5.87
+80.97%
3.24
Change In Receivables
—
0.00
-100.00%
6.10
+44.76%
4.21
Changes In Account Receivables
—
0.00
-100.00%
1.00
+212.87%
-0.89
Change In Inventory
—
0.00
+100.00%
-1.01
+73.79%
-3.87
Change In Prepaid Assets
-0.41
-271.43%
0.24
-74.63%
0.94
+311.40%
0.23
Change In Payables And Accrued Expense
1.07
+133.35%
-3.22
-6944.68%
0.05
-98.25%
2.68
Change In Accrued Expense
-0.76
+56.08%
-1.73
-356.85%
0.67
-53.43%
1.44
Change In Payable
1.83
+222.80%
-1.49
-138.56%
-0.62
-150.44%
1.24
Change In Account Payable
1.83
+222.80%
-1.49
-138.56%
-0.62
-150.44%
1.24
Change In Other Working Capital
0.25
+25.00%
0.20
+300.00%
-0.10
-1528.57%
0.01
Change In Other Current Liabilities
-0.44
-12.08%
-0.39
-285.15%
-0.10
-573.33%
-0.01
Investing Cash Flow
0.74
-18.10%
0.91
-87.07%
7.01
+236.71%
-5.13
Cash Flow From Continuing Investing Activities
0.74
-18.10%
0.91
-87.07%
7.01
+236.71%
-5.13
Net PPE Purchase And Sale
-0.02
+82.98%
-0.09
+97.00%
-3.14
+57.19%
-7.33
Purchase Of PPE
-0.02
+92.38%
-0.21
+96.34%
-5.74
+21.72%
-7.33
Sale Of PPE
0.00
-100.00%
0.12
-95.54%
2.60
0.00
Capital Expenditure
-0.02
+92.38%
-0.21
+96.34%
-5.74
+50.66%
-11.63
Net Investment Purchase And Sale
—
0.00
-100.00%
10.84
+66.68%
6.50
Purchase Of Investment
—
—
0.00
+100.00%
-7.12
Sale Of Investment
—
0.00
-100.00%
10.84
-20.41%
13.62
Net Business Purchase And Sale
—
0.00
+100.00%
-0.69
0.00
Purchase Of Business
—
0.00
+100.00%
-0.69
0.00
Net Intangibles Purchase And Sale
0.00
-100.00%
1.00
0.00
+100.00%
-4.30
Purchase Of Intangibles
—
—
0.00
+100.00%
-4.30
Net Other Investing Changes
—
—
—
—
Financing Cash Flow
8.93
-63.55%
24.49
+964.49%
2.30
+137.57%
-6.12
Cash Flow From Continuing Financing Activities
8.93
-63.55%
24.49
+964.49%
2.30
+137.57%
-6.12
Net Issuance Payments Of Debt
-0.69
+38.93%
-1.14
+87.53%
-9.12
-56.52%
-5.83
Issuance Of Debt
0.00
-100.00%
0.90
+79.00%
0.50
0.00
Repayment Of Debt
-0.69
+65.81%
-2.03
+78.88%
-9.62
-65.09%
-5.83
Long Term Debt Issuance
0.00
-100.00%
0.90
+79.00%
0.50
0.00
Long Term Debt Payments
-0.69
-33.65%
-0.52
-69.38%
-0.31
+94.73%
-5.83
Net Long Term Debt Issuance
-0.69
-285.33%
0.38
+94.30%
0.19
+103.31%
-5.83
Short Term Debt Payments
0.00
+100.00%
-1.51
+83.76%
-9.32
0.00
Net Short Term Debt Issuance
0.00
+100.00%
-1.51
+83.76%
-9.32
0.00
Net Common Stock Issuance
3.54
-86.12%
25.52
+122.89%
11.45
0.00
Common Stock Payments
0.00
+100.00%
-0.01
+82.05%
-0.04
0.00
Repurchase Of Capital Stock
0.00
+100.00%
-0.01
+82.05%
-0.04
0.00
Proceeds From Stock Option Exercised
6.38
0.00
0.00
-100.00%
0.08
Net Other Financing Charges
-0.29
-353.45%
0.12
+627.27%
-0.02
+94.09%
-0.37
Changes In Cash
-5.63
-182.28%
6.85
+132.41%
-21.13
+56.65%
-48.73
Effect Of Exchange Rate Changes
—
0.00
-100.00%
0.03
0.00
Beginning Cash Position
14.43
+90.33%
7.58
-73.57%
28.67
-62.96%
77.40
End Cash Position
8.79
-39.05%
14.43
+90.33%
7.58
-73.57%
28.67
Free Cash Flow
-15.32
+18.35%
-18.76
+48.13%
-36.17
+26.34%
-49.11
Interest Paid Supplemental Data
0.21
-71.70%
0.75
+9.02%
0.69
-34.26%
1.04
Amortization Of Securities
—
0.00
-100.00%
0.07
-78.53%
0.31
Common Stock Issuance
3.54
-86.13%
25.52
+122.19%
11.49
0.00
Interest Received CFI
0.76
0.00
—
—
Issuance Of Capital Stock
3.54
-86.13%
25.52
+122.19%
11.49
0.00
Net Preferred Stock Issuance
—
—
—
0.00
Preferred Stock Issuance
—
—
—
0.00
Sale Of Intangibles
0.00
-100.00%
1.00
0.00
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category